Omental Fat vs Visceral Fat: Key Differences

Omental fat vs visceral fat is a distinction that matters far more than most people realise. Visceral fat is the broad term for all fat stored deep within the abdominal cavity, surrounding the internal organs, while omental fat is a specific and particularly metabolically active depot within that category. Both carry significant health risks, but omental fat, which drains directly into the portal vein and liver, has an outsized influence on insulin resistance, inflammation, and cardiometabolic disease. Understanding the difference can help you make sense of clinical measurements, health risks, and the most effective strategies for reducing deep abdominal fat.

What is the difference between omental fat and visceral fat?

Omental fat is a specific depot within the greater omentum and a subset of visceral fat, which is the broader term for all intra-abdominal fat surrounding the organs. Omental fat is particularly metabolically active and drains directly into the portal vein.

Omental fat is a specific depot of visceral fat contained within the greater omentum, a large fold of fatty tissue that hangs from the stomach and drapes over the intestines, whereas visceral fat is the broader term for all fat stored within the abdominal cavity surrounding the internal organs. Understanding this distinction matters clinically because, while all visceral fat carries metabolic risk, omental fat has been associated with particularly high metabolic activity and is closely linked with systemic inflammation and insulin resistance.

Visceral fat as a category includes omental fat, mesenteric fat (surrounding the intestines), and perinephric fat (around the kidneys). Subcutaneous fat, by contrast, sits beneath the skin and above the abdominal muscle wall. Although subcutaneous fat is visible and measurable by pinching the skin, visceral and omental fat lie deep within the abdominal cavity and cannot be assessed by touch alone.

The omentum is not simply a passive fat store. It contains a high density of immune cells and acts as a reservoir for inflammatory mediators. Because omental fat drains directly into the portal vein (as do other intra-abdominal depots, though the omentum is particularly well studied in this regard), the fatty acids and cytokines it releases travel directly to the liver. This is one reason this particular fat depot has an outsized effect on metabolic health compared with fat stored elsewhere in the body.

Why does fat stored around your organs carry more health risks?

Visceral and omental fat release high levels of free fatty acids and inflammatory cytokines directly into the portal circulation, promoting liver fat accumulation, insulin resistance, and atherosclerosis. These risks occur even at a normal BMI.

Fat stored around the organs carries greater health risks than subcutaneous fat because visceral and omental adipose tissue is metabolically far more active, releasing higher levels of free fatty acids, inflammatory cytokines such as interleukin-6 and tumour necrosis factor-alpha, and hormones that disrupt insulin signalling. This metabolic activity is not proportional to the volume of fat alone but reflects the unique biological properties of these deep depots.

The portal drainage pathway is central to understanding the risk. Free fatty acids released from omental fat flow directly into the portal circulation and reach the liver in high concentrations, promoting hepatic fat accumulation, increased glucose production, and dyslipidaemia. This mechanism helps explain why individuals with predominantly central adiposity can develop metabolic complications even at a body mass index (BMI) that falls within the normal range.

Visceral fat also produces lower levels of adiponectin, a hormone with anti-inflammatory and insulin-sensitising properties, compared with subcutaneous fat.^[7][8] Reduced adiponectin combined with elevated inflammatory signalling creates a hormonal environment that promotes insulin resistance, endothelial dysfunction, and atherosclerosis. Research published in journals including the European Heart Journal has consistently shown that visceral fat volume is a stronger predictor of cardiometabolic risk than total body fat or BMI alone.^[17]

This is why waist circumference, waist-to-hip ratio, and waist-to-height ratio are used clinically alongside weight. Current UK guidance recommends that a waist-to-height ratio of 0.5 or above is used as an additional indicator of elevated cardiometabolic risk, alongside BMI and waist circumference.

How do doctors measure and assess deep abdominal fat in the UK?

UK clinicians use waist circumference, waist-to-hip ratio, and waist-to-height ratio as primary tools; a waist-to-height ratio of 0.5 or above indicates elevated cardiometabolic risk. MRI or CT can precisely quantify visceral fat when clinically indicated.

Doctors in the UK assess deep abdominal fat primarily through clinical measurements and, where indicated, imaging, because visceral and omental fat cannot be directly quantified without specialist scanning. The most widely used clinical tools are waist circumference, waist-to-hip ratio, and waist-to-height ratio, all of which are recommended as part of cardiovascular and metabolic risk assessment in UK clinical practice.

NICE guidance on the identification and classification of overweight and obesity recommends that waist circumference be interpreted alongside BMI and, increasingly, waist-to-height ratio (a ratio of 0.5 or above indicating elevated risk). Action levels for waist circumference in UK clinical practice are generally set at above 94 cm for men and above 80 cm for women, with higher-risk thresholds at above 102 cm and above 88 cm respectively. These thresholds are based on WHO and IDF guidance and may differ for people of South Asian, Chinese, or other ethnic backgrounds, in whom cardiometabolic risk occurs at lower measurements.

Where more precise quantification is needed, for example in research settings or complex clinical cases, magnetic resonance imaging (MRI) and computed tomography (CT) scanning can directly measure visceral fat volume. Dual-energy X-ray absorptiometry (DEXA) scanning can also estimate regional fat distribution. These investigations are not routinely commissioned on the NHS solely for fat assessment; access depends on clinical indication and local pathway decisions.

Bioelectrical impedance analysis (BIA) devices, available in some GP practices and pharmacies, can estimate body fat percentage and sometimes visceral fat scores, though their accuracy varies. A GP assessment remains the appropriate starting point for anyone concerned about their abdominal fat distribution and associated health risks.

Which conditions are linked to high levels of omental and visceral fat?

High visceral and omental fat independently increases risk of type 2 diabetes, cardiovascular disease, NAFLD/MASLD, certain cancers, and obstructive sleep apnoea, even after adjusting for total body weight.

High levels of omental and visceral fat are independently associated with an increased risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD, now increasingly termed metabolic dysfunction-associated steatotic liver disease or MASLD), certain cancers, and obstructive sleep apnoea. These associations hold even after adjusting for overall body weight, reinforcing that fat distribution matters as much as total fat mass.

The link with type 2 diabetes is particularly well established. Visceral fat drives hepatic insulin resistance and impairs pancreatic beta-cell function over time. NICE public health guidance on preventing type 2 diabetes in high-risk groups identifies central adiposity as a key modifiable risk factor. Similarly, cardiovascular risk is elevated because visceral fat promotes atherogenic dyslipidaemia (raised triglycerides, low HDL cholesterol), hypertension, and systemic inflammation, all of which contribute to atherosclerotic plaque formation.

NAFLD affects an estimated up to one in three adults in the UK to some degree, according to the British Liver Trust, and visceral fat accumulation is a primary driver of hepatic steatosis and progression to non-alcoholic steatohepatitis (NASH).^[9] Certain cancers, including colorectal, endometrial, and postmenopausal breast cancer, are also associated with excess visceral adiposity, likely through inflammatory and hormonal pathways, as documented in World Cancer Research Fund reports on body fatness and cancer risk. Obstructive sleep apnoea is worsened by fat deposition around the upper airway and thorax, and weight reduction, including reduction of visceral fat, is a first-line management strategy recommended in NICE guidance on obstructive sleep apnoea.^[10]

Can you reduce deep abdominal fat, and what does the evidence say?

Visceral fat responds more readily to energy deficit than subcutaneous fat; aerobic exercise, Mediterranean-style diet, GLP-1 receptor agonists, and bariatric surgery all produce measurable reductions in visceral fat volume.

Deep abdominal fat, including omental and visceral fat, can be reduced through sustained lifestyle changes and, in eligible individuals, through pharmacological or surgical interventions, with evidence consistently showing that visceral fat responds more readily to energy deficit than subcutaneous fat. This preferential loss of visceral fat with weight reduction is one reason that even modest weight loss of 5 to 10 per cent of body weight can produce meaningful improvements in metabolic risk markers.

Lifestyle interventions form the foundation of management:

• Dietary change: Reducing overall energy intake, particularly from ultra-processed foods and refined carbohydrates, is associated with reductions in visceral fat. Mediterranean-style dietary patterns have shown benefit in multiple randomised controlled trials examining visceral adiposity as an outcome.^[13]

• Physical activity: Both aerobic exercise and resistance training reduce visceral fat, with some evidence that aerobic exercise has a preferential effect on visceral depots even without significant change in total body weight.^[11][12] The UK Chief Medical Officers' physical activity guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[1][2]

• Sleep and stress: Chronic sleep deprivation and elevated cortisol from psychological stress promote visceral fat accumulation, and addressing these factors is part of a comprehensive approach.

For individuals with obesity-related comorbidities, NICE-recommended pharmacological treatments may support visceral fat reduction as part of broader weight management. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, including those appraised by NICE for weight management, have demonstrated reductions in visceral fat volume in clinical trial imaging substudies. Bariatric surgery, for which NICE sets out specific eligibility criteria, produces the most substantial and sustained reductions in visceral fat and is associated with remission of type 2 diabetes and cardiovascular risk reduction.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered.

When should you speak to your GP about your abdominal fat levels?

Speak to your GP if your waist circumference exceeds action thresholds, you have raised blood glucose, high triglycerides, low HDL, or elevated blood pressure, as these may indicate metabolic syndrome requiring formal cardiovascular risk assessment.

You should speak to your GP about your abdominal fat levels if your waist circumference exceeds the action thresholds for your sex and ethnicity, if you have a family history of type 2 diabetes or cardiovascular disease, or if you have noticed unexplained changes in your weight distribution alongside symptoms such as fatigue, increased thirst, or breathlessness. Early assessment allows your GP to calculate your overall cardiometabolic risk and arrange appropriate investigations.

A GP consultation is also warranted if you have already been told you have raised blood glucose, high triglycerides, low HDL cholesterol, or elevated blood pressure, as these findings in combination with central adiposity may indicate metabolic syndrome, which carries a substantially elevated risk of cardiovascular events and type 2 diabetes. NICE guidance on cardiovascular risk assessment and lipid modification recommends that adults with a BMI of 25 or above (or 23 or above for people of South Asian origin) and additional risk factors are offered a formal cardiovascular risk assessment using a validated tool such as QRISK3.^[16]

If you are experiencing symptoms that could indicate a serious acute condition, such as severe abdominal pain, jaundice, or sudden onset breathlessness, contact NHS 111 for urgent advice or attend A&E if the situation is life-threatening. For ongoing concerns about weight and metabolic health, your GP can refer you to NHS weight management services, dietetic support, or specialist clinics depending on your clinical needs; eligibility and referral pathways vary according to local Integrated Care Board (ICB) commissioning policies. Suspected adverse effects from any prescribed medicine should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. UK Chief Medical Officers' Physical Activity Guidelines.
2. Physical Activity Guidelines for Adults Aged 19 to 64.
3. Overweight and Obesity Management (NG246): Identifying and Assessing Overweight, Obesity and Central Adiposity.
4. A simple cut-off for waist-to-height ratio (0·5) can act as an indicator of cardiometabolic risk.
5. Keep the Size of Your Waist to Less Than Half of Your Height – NICE Recommends.
6. Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance.
7. Subcutaneous and Visceral Adipose Tissue: Structural and Functional Differences.
8. Pathophysiology and Pathogenesis of Visceral Fat Obesity.
9. Liver Disease: Applying All Our Health.
10. Obstructive Sleep Apnoea/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome in Over 16s (NG202).
11. A Dose-Response Relation Between Aerobic Exercise and Visceral Fat Reduction.
12. Aerobic Exercise and Weight Loss in Adults: A Systematic Review.
13. Ad Libitum Mediterranean Diet Reduces Subcutaneous but Not Visceral Fat in Patients with Coronary Heart Disease: A Randomised Controlled Pilot Study.
14. Ethnic-Specific Obesity Cutoffs for Diabetes Risk: Cross-Sectional Study of 490,288 UK Biobank Participants.
15. Body Mass Index and Waist Circumference Cut-Points in Multi-Ethnic Populations from the UK and India.
16. Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification (NG238).
17. Revisiting the obesity paradox: visceral fat distribution outperforms BMI in predicting mortality and cardiometabolic risk.

Frequently Asked Questions